News|Videos|November 28, 2023
Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
4
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
5